Psoriasis patients complete survey on treatment needs

Novartis, has released new data from a patient preference survey showing psoriasis patients want their treatment to go beyond just clear skin and safety. This study of 300 psoriasis patients is being presented during a poster session at the 27th European Academy of Dermatology and Venereology (EADV). 

Results confirmed that clear skin is the most preferred treatment attribute, which is consistent with previous patient preference surveys in psoriasis. Results also show patients expect additional benefits from their treatment that are not traditionally assessed in patient surveys, including the number of years of proven efficacy and safety data in large clinical trials and no injection site reactions.

In a separate ranking incorporating additional characteristics, patients ranked the effectiveness in treating multiple manifestations of psoriatic disease (including PsA, nail, palmoplantar and scalp), and complete symptom relief, as being important, after risk of side effects and clear skin (including time to achieve clear skin). Least important were the number of injections per dose and injection frequency.

Psoriatic disease is complex and multifaceted. Up to 40% of patients may develop PsA. In the long term, up to 90% of psoriasis patients may also develop nail, palmoplantar psoriasis (of the palms of the hands and soles of the feet), or scalp psoriasis. These manifestations are associated with a greater burden on patients’ life.

Professor Matthias Augustin, Director Institute of Health Care Research in Dermatology and Nursing, University of Hamburg said, “It’s relevant to understand from psoriasis patients which additional benefits from their treatment they want besides clear skin and safety. From the findings of this survey, consistent and sustained long term efficacy and safety from large clinical studies, no pain at injection site or efficacy in all manifestations of psoriatic disease could be influential when choosing a treatment for moderate-to-severe psoriasis.”

Sam Khalil, PhD, Head Worldwide Medical Affairs, Immunology, Hepatology and Dermatology said, “The survey will help Novartis and dermatologists better understand patient preference in selecting psoriatic disease treatment options. It supports Novartis goal of leadership in immuno-dermatology and our commitment to improving patient care. Reimagining medicine for patients, starts by listening to what patients truly want and need.”